Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Blood-Borne Infections

ClinicalTrials.gov lists 10,358 trials for Blood-Borne Infections or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 1,074.

MeSH D000086982 Infections C01 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1,535 Phase 1/2 Phase 1/2 298 Phase 2 Phase 2 1,441 Phase 2/3 Phase 2/3 138 Phase 3 Phase 3 1,195 Phase 4 Phase 4 1,157 Not applicable Not applicable 2,437 Observational Observational 2,132 Phase 1 Phase 1 1,535 Phase 1/2 Phase 1/2 298 Phase 2 Phase 2 1,441 Phase 2/3 Phase 2/3 138 Phase 3 Phase 3 1,195 Phase 4 Phase 4 1,157 Not applicable Not applicable 2,437 Observational Observational 2,132

Trials per phase

1 more section with rows

5 of the 10,358 trials are tagged with Blood-Borne Infections itself; the rest are tagged with a narrower condition beneath it.

Get the Blood-Borne Infections report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Blood-Borne Infections trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 22 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 491

1990: 5 trials (Observational 1, Phase 3 2, Phase 2 2) 1991: 3 trials (Observational 1, Phase 3 1, Phase 2 1) 1992: 11 trials (Observational 6, Not applicable 1, Phase 3 2, Phase 2 1, Phase 1 1) 1993: 7 trials (Observational 2, Phase 3 2, Phase 2 3) 1994: 17 trials (Observational 7, Not applicable 3, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 1 3) 1995: 19 trials (Observational 4, Not applicable 2, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 5, Phase 1 3) 1996: 18 trials (Observational 7, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1 2) 1997: 40 trials (Observational 12, Not applicable 3, Phase 3 10, Phase 2/3 1, Phase 2 5, Phase 1/2 3, Phase 1 6) 1998: 33 trials (Observational 9, Not applicable 3, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 9, Phase 1 5) 1999: 83 trials (Observational 15, Not applicable 8, Phase 4 7, Phase 3 19, Phase 2/3 1, Phase 2 19, Phase 1/2 1, Phase 1 13) 2000: 84 trials (Other 1, Observational 23, Not applicable 6, Phase 4 6, Phase 3 25, Phase 2 14, Phase 1/2 1, Phase 1 8) 2001: 108 trials (Other 1, Observational 23, Not applicable 13, Phase 4 7, Phase 3 24, Phase 2/3 3, Phase 2 25, Phase 1/2 6, Phase 1 6) 2002: 174 trials (Other 1, Observational 34, Not applicable 21, Phase 4 25, Phase 3 43, Phase 2/3 5, Phase 2 35, Phase 1/2 3, Phase 1 7) 2003: 235 trials (Other 2, Observational 40, Not applicable 31, Phase 4 44, Phase 3 44, Phase 2/3 2, Phase 2 40, Phase 1/2 13, Phase 1 19) 2004: 289 trials (Other 2, Observational 53, Not applicable 32, Phase 4 48, Phase 3 61, Phase 2/3 7, Phase 2 51, Phase 1/2 10, Phase 1 25) 2005: 376 trials (Observational 78, Not applicable 43, Phase 4 74, Phase 3 55, Phase 2/3 5, Phase 2 73, Phase 1/2 13, Phase 1 35) 2006: 373 trials (Observational 61, Not applicable 45, Phase 4 60, Phase 3 69, Phase 2/3 10, Phase 2 62, Phase 1/2 17, Phase 1 49) 2007: 393 trials (Observational 70, Not applicable 56, Phase 4 67, Phase 3 60, Phase 2/3 10, Phase 2 63, Phase 1/2 16, Phase 1 51) 2008: 428 trials (Observational 90, Not applicable 69, Phase 4 82, Phase 3 50, Phase 2/3 5, Phase 2 59, Phase 1/2 16, Phase 1 57) 2009: 491 trials (Observational 106, Not applicable 65, Phase 4 74, Phase 3 35, Phase 2/3 6, Phase 2 94, Phase 1/2 19, Phase 1 92) 2010: 401 trials (Observational 88, Not applicable 47, Phase 4 51, Phase 3 48, Phase 2/3 3, Phase 2 72, Phase 1/2 13, Phase 1 79) 2011: 434 trials (Observational 93, Not applicable 61, Phase 4 54, Phase 3 76, Phase 2/3 5, Phase 2 54, Phase 1/2 16, Phase 1 75) 2012: 384 trials (Other 1, Observational 94, Not applicable 61, Phase 4 33, Phase 3 74, Phase 2/3 6, Phase 2 51, Phase 1/2 11, Phase 1 53) 2013: 349 trials (Observational 67, Not applicable 73, Phase 4 45, Phase 3 48, Phase 2/3 9, Phase 2 47, Phase 1/2 15, Phase 1 45) 2014: 361 trials (Observational 67, Not applicable 66, Phase 4 36, Phase 3 59, Phase 2/3 8, Phase 2 44, Phase 1/2 15, Phase 1 66) 2015: 421 trials (Observational 94, Not applicable 83, Phase 4 63, Phase 3 52, Phase 2/3 7, Phase 2 51, Phase 1/2 9, Phase 1 62) 2016: 375 trials (Observational 81, Not applicable 99, Phase 4 47, Phase 3 46, Phase 2/3 10, Phase 2 36, Phase 1/2 7, Phase 1 49) 2017: 423 trials (Observational 103, Not applicable 137, Phase 4 53, Phase 3 34, Phase 2/3 3, Phase 2 29, Phase 1/2 10, Phase 1 54) 2018: 383 trials (Observational 102, Not applicable 119, Phase 4 51, Phase 3 18, Phase 2/3 5, Phase 2 29, Phase 1/2 13, Phase 1 46) 2019: 429 trials (Observational 107, Not applicable 159, Phase 4 41, Phase 3 19, Phase 2/3 5, Phase 2 40, Phase 1/2 10, Phase 1 48) 2020: 332 trials (Observational 79, Not applicable 116, Phase 4 37, Phase 3 16, Phase 2/3 2, Phase 2 33, Phase 1/2 8, Phase 1 41) 2021: 347 trials (Observational 89, Not applicable 130, Phase 4 36, Phase 3 10, Phase 2/3 2, Phase 2 37, Phase 1/2 4, Phase 1 39) 2022: 340 trials (Observational 87, Not applicable 135, Phase 4 29, Phase 3 8, Phase 2/3 2, Phase 2 31, Phase 1/2 5, Phase 1 43) 2023: 301 trials (Observational 76, Not applicable 126, Phase 4 20, Phase 3 12, Phase 2/3 3, Phase 2 24, Phase 1/2 8, Phase 1 32) 2024: 268 trials (Observational 73, Not applicable 109, Phase 4 11, Phase 3 9, Phase 2/3 1, Phase 2 21, Phase 1/2 9, Phase 1 35) 2025: 214 trials (Observational 57, Not applicable 81, Phase 4 15, Phase 3 12, Phase 2/3 4, Phase 2 20, Phase 1/2 6, Phase 1 19)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 204
2025 214
2024 268
2023 301
2022 340
2021 347
2020 332
2019 429
2018 383
2017 423

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 230 trials starting in 2026 and about 230 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 427 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 6,524 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Blood-Borne Infections trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1,535
Phase 1/2 298
Phase 2 1,441
Phase 2/3 138
Phase 3 1,195
Phase 4 1,157
Not applicable 2,437
Observational 2,132
Expanded access 25

How many Blood-Borne Infections trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 209
Recruiting 440
Enrolling by invitation 37
Active, not recruiting 220
Available 3

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Blood-Borne Infections trials? (12)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 1,074
Merck Sharp & Dohme LLC 268
ViiV Healthcare 250
Gilead Sciences 239
GlaxoSmithKline 224

Showing 5 of 12 sponsors.

Start your 14-day trial Email me all 12 sponsors as a PDF

Which drugs are being tested for Blood-Borne Infections? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Zidovudine 277
PEGinterferon alfa-2a 245
LAMIVUDINE 221
Entecavir 152
Efavirenz 146

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Ribavirine 559
Ritonavir (RTV) low 202
tenofovir disproxil fumarate 182
didanosine, ddI (drug) 120
Stavudine 113

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Blood-Borne Infections trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 1,876 383
Anaemia 1,116 229
Gastroenteritis 981 223
Any Event in SOC 823 16
Neutropenia 795 116

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: publications, prevalence, and rare-disease identity.

Browse all condition evidence pages